title: Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Fabbiani
authors.forename: Laura
authors.initials: L
authors.lastname: Bracciale
authors.forename: Maria
authors.initials: M
authors.lastname: Doino
authors.forename: Alessandro
authors.initials: A
authors.lastname: D'Avino
authors.forename: Angela
authors.initials: A
authors.lastname: Marzocchetti
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Navarra
authors.forename: Roberto
authors.initials: R
authors.lastname: Cauda
authors.forename: Andrea
authors.initials: A
authors.lastname: De Luca
authors.forename: Simona
authors.initials: S
authors.lastname: Di Giambenedetto
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D000069446:Atazanavir Sulfate; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects*; D063065:Organophosphonates / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D019438:Ritonavir / Q000008:administration & dosage; D000068698:Tenofovir; D052878:Urolithiasis / Q000139:chemically induced*
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D063065:Organophosphonates; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D000069446:Atazanavir Sulfate; D000068698:Tenofovir; D000225:Adenine; D019438:Ritonavir